文献速递胃肠外科

SPONGE试验:海绵辅助与Trendelenburg体位在腹腔镜乙状结肠和直肠癌手术中的随机临床试验

SPONGE-assisted versus Trendelenburg position surgery in laparoscopic sigmoid and rectal cancer surgery (SPONGE trial): randomized clinical trial.
PubMed 文献 · Br J Surg · 2022-01-01

SPONGE试验是一项嵌套于荷兰全国前瞻性观察队列的单中心随机临床试验,采用TwiCs设计,比较海绵辅助与Trendelenburg体位在乙状结肠或直肠癌择期腹腔镜或机器人手术中的效果。共150例患者纳入分析(每组75例),主要结局术后住院时间无统计学显著差异(中位5天 vs 4天,P=0.06),30天并发症、再入院率及死亡率亦无显著差异。结论认为海绵辅助手术并未减少住院时间或围术期发病率或死亡率。

要点

  • 海绵辅助与Trendelenburg体位手术的术后中位住院时间分别为5天和4天,差异无统计学意义(P=0.06)。
  • 两组30天并发症(30% vs 31%)、再入院率(8% vs 15%)及死亡率(0% vs 1%)均无显著差异。
  • 未观察到器械相关不良事件,但试验对干预组患者和医生未设盲。

核心结论

  • 海绵辅助腹腔镜/机器人手术并未减少术后住院时间,也未改善围术期发病率或死亡率。

研究设计与样本

  • SPONGE试验为单中心随机临床试验,嵌套于荷兰全国前瞻性观察队列,采用TwiCs设计。
  • 纳入接受择期腹腔镜或机器人手术的乙状结肠或直肠癌患者,按1:1区组随机分配。
  • 主要结局为术后住院时间,采用Mann-Whitney U检验比较;次要结局包括并发症比例、再入院或死亡率,采用χ2检验,行意向性治疗和符合方案分析。
  • 试验对干预组患者和医生未设盲。

主要发现

  • 术后中位住院时间海绵辅助组为5天,Trendelenburg组为4天,差异无统计学意义(P=0.06)。
  • 30天术后并发症发生率海绵辅助组为30%,Trendelenburg组为31%(P=1.00)。
  • 再入院率海绵辅助组为8%,Trendelenburg组为15%(P=0.30)。
  • 死亡率海绵辅助组为0%,Trendelenburg组为1%(P=1.00)。
  • 符合方案分析显示相似结果,未观察到器械相关不良事件。

临床怎么用

  • 对于乙状结肠或直肠癌的腹腔镜/机器人手术,海绵辅助技术可作为Trendelenburg体位的替代选择,但不应期望其缩短住院时间或降低并发症。
  • 临床决策需结合患者具体情况和术者经验,权衡两种方式的利弊。

局限性

  • 单中心研究,样本量有限(150例纳入分析)。
  • 试验对干预组患者和医生未设盲,可能存在偏倚。
  • 研究嵌套于观察性队列,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In minimally invasive surgery of the sigmoid colon and rectum a retractor sponge has been introduced as an alternative to the Trendelenburg position. This randomized clinical trial (RCT) compared postoperative duration of hospital stay and perioperative outcomes in patients with sigmoid or rectal cancer undergoing sponge-assisted versus Trendelenburg position surgery. METHODS: The SPONGE trial is a single-centre RCT nested within the Dutch nationwide prospective observational cohort of patients with colorectal cancer, and follows the Trials within Cohorts (TwiCs) design. Patients with sigmoid or rectal cancer undergoing elective laparoscopic or robotic surgery were randomized to either sponge-assisted or Trendelenburg surgery on a 1:1 basis using block randomization. Duration of postoperative hospital stay was the primary outcome and was compared using the Mann-Whitney U test. Secondary endpoints included the proportion of complications, readmissions, or mortality versus the χ2 test in intention-to-treat and per-protocol analyses. This trial was not blinded for patients in the intervention arm or physicians. RESULTS: Between November 2015 and June 2021, 82 patients were randomized to sponge-assisted surgery and 81 to Trendelenburg surgery. After post-randomization exclusion, 150 patients remained for analyses (75 patients per arm). There was no statistically significant difference in median duration of hospital stay (5 days versus 4 days, respectively; P = 0.06), 30-day postoperative complications (30 per cent versus 31 per cent; P = 1.00), readmission rate (8 per cent versus 15 per cent; P = 0.30), or mortality (0 per cent versus 1 per cent, P = 1.00). The per-protocol analysis showed similar results. No adverse device events were seen. CONCLUSION: Sponge-assisted laparoscopic/robotic surgery does not reduce the duration of hospital stay, or perioperative morbidity or mortality. TRIAL REGISTRATION: NCT02574013 (http://www.clinicaltrials.gov).

来源:Br J Surg,查看原文。版权归原作者所有。

引用

  1. Fahim M, Couwenberg A, Verweij ME, et al. SPONGE-assisted versus Trendelenburg position surgery in laparoscopic sigmoid and rectal cancer surgery (SPONGE trial): randomized clinical trial. Br J Surg. 2022. PMID: 35909251. doi:10.1093/bjs/znac249

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。